Vertex Pharmaceuticals (VRTX) Competitors $447.18 +6.52 (+1.48%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VRTX vs. AMGN, GILD, REGN, ALNY, BIIB, UTHR, NBIX, BMRN, INCY, and EXELShould you be buying Vertex Pharmaceuticals stock or one of its competitors? The main competitors of Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Incyte (INCY), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry. Vertex Pharmaceuticals vs. Amgen Gilead Sciences Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Incyte Exelixis Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, community ranking, risk, analyst recommendations and media sentiment. Do institutionals and insiders believe in AMGN or VRTX? 76.5% of Amgen shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.8% of Amgen shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community favor AMGN or VRTX? Vertex Pharmaceuticals received 49 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 74.83% of users gave Vertex Pharmaceuticals an outperform vote while only 71.71% of users gave Amgen an outperform vote. CompanyUnderperformOutperformAmgenOutperform Votes155971.71% Underperform Votes61528.29% Vertex PharmaceuticalsOutperform Votes160874.83% Underperform Votes54125.17% Which has preferable valuation and earnings, AMGN or VRTX? Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$34.13B4.33$4.09B$10.9625.09Vertex Pharmaceuticals$11.10B10.35-$535.60M-$3.92-114.08 Is AMGN or VRTX more profitable? Amgen has a net margin of 12.24% compared to Vertex Pharmaceuticals' net margin of -4.86%. Amgen's return on equity of 176.32% beat Vertex Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amgen12.24% 176.32% 11.71% Vertex Pharmaceuticals -4.86%-2.02%-1.49% Does the media favor AMGN or VRTX? In the previous week, Amgen had 10 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 38 mentions for Amgen and 28 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.48 beat Amgen's score of 1.27 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 24 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Vertex Pharmaceuticals 23 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate AMGN or VRTX? Amgen currently has a consensus target price of $309.22, indicating a potential upside of 12.44%. Vertex Pharmaceuticals has a consensus target price of $515.04, indicating a potential upside of 15.18%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 2 Sell rating(s) 12 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.38Vertex Pharmaceuticals 0 Sell rating(s) 13 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.59 Which has more risk & volatility, AMGN or VRTX? Amgen has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. SummaryAmgen beats Vertex Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Vertex Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRTX vs. The Competition Export to ExcelMetricVertex PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$114.83B$6.55B$5.43B$8.47BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-203.269.1426.8320.05Price / Sales10.35257.54394.48119.51Price / CashN/A65.8538.2534.62Price / Book7.006.546.874.61Net Income-$535.60M$143.51M$3.22B$248.10M7 Day Performance3.51%4.66%5.65%2.88%1 Month Performance-8.57%10.63%13.54%15.41%1 Year Performance0.29%-1.05%18.16%7.68% Vertex Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRTXVertex Pharmaceuticals4.6606 of 5 stars$447.18+1.5%$515.04+15.2%+0.3%$114.83B$11.10B-203.264,800Positive NewsAMGNAmgen4.622 of 5 stars$275.03+3.4%$310.23+12.8%-12.6%$148.11B$34.13B36.4825,200Positive NewsAnalyst UpgradeGILDGilead Sciences4.6931 of 5 stars$104.01+7.3%$110.55+6.3%+60.7%$129.57B$28.74B281.2417,000Positive NewsOptions VolumeREGNRegeneron Pharmaceuticals4.8231 of 5 stars$576.35+9.2%$892.60+54.9%-37.7%$63.03B$14.09B15.0611,900Trending NewsDividend AnnouncementGap UpALNYAlnylam Pharmaceuticals3.7096 of 5 stars$266.32+6.0%$319.17+19.8%+94.1%$34.83B$2.35B-123.112,000Positive NewsBIIBBiogen4.9168 of 5 stars$124.12+5.0%$191.30+54.1%-43.6%$18.21B$9.82B11.118,720Analyst RevisionUTHRUnited Therapeutics4.9819 of 5 stars$311.40+3.3%$392.00+25.9%+12.7%$14.05B$2.99B13.68980NBIXNeurocrine Biosciences4.9305 of 5 stars$120.12+3.8%$162.00+34.9%-13.2%$11.87B$2.41B36.451,200Positive NewsBMRNBioMarin Pharmaceutical4.9841 of 5 stars$61.67+4.8%$93.45+51.5%-22.2%$11.83B$2.95B28.053,080Positive NewsInsider TradeGap UpINCYIncyte4.8942 of 5 stars$60.93+3.3%$73.53+20.7%+14.2%$11.79B$4.41B225.512,320Positive NewsEXELExelixis4.0655 of 5 stars$37.09+2.6%$37.59+1.3%+110.6%$10.25B$2.17B21.011,220Positive News Related Companies and Tools Related Companies Amgen Alternatives Gilead Sciences Alternatives Regeneron Pharmaceuticals Alternatives Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Incyte Alternatives Exelixis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRTX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Vertex Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.